Latest International Market Expansion News

Rubicon Water’s FY25 results reveal strong global revenue growth led by the US and EMEA, alongside a narrowing EBITDA loss despite operational headwinds and strategic restructuring in China.

Prophecy International Holdings has agreed to acquire Complexica in a transformative merger, creating Complexica Group Limited, an ASX-listed AI pure play software company with enhanced scale and growth potential.

Vitrafy Life Sciences announces a leadership change with CEO Kate Munnings retiring and co-founder Brent Owens stepping up to lead the company’s next growth phase.

Eden Innovations reports a striking 114% year-on-year jump in Q4 US sales of its EdenCrete® products, alongside a 50% annual sales increase and significant debt reduction plans.

Sprintex has advanced a promising trial with a major Dutch agribusiness, potentially unlocking €4.8 million in sales, while also securing a significant private-label contract in China’s booming aquaculture sector.

Merino & Co reported a robust quarter highlighted by the successful launch of its Merino possum range, strategic international hires, and a solid cash position of $3.02 million, positioning the company for sustained expansion.

RLF AgTech reports a robust 74% increase in customer cash receipts for FY2025, alongside a significant expansion of its Australian distribution network and strong pre-orders from China, signaling a promising start to FY2026.

Biome Australia Limited has reported a 69% increase in international sales revenue for FY25, reaching $1.5 million, driven by new strategic distribution agreements across Ireland, New Zealand, and Canada.

Compumedics Limited has reported record sales orders and a return to profitability in FY25, setting the stage for robust growth in FY26 driven by US market traction and SaaS expansion.

PainChek Limited reports a robust quarter with a 10% rise in annual recurring revenue and expanding global client base, underpinned by strong licence retention and positive clinical validation.

Bioxyne Limited has upgraded its FY2025 revenue guidance to approximately $28 million, driven by strong domestic performance and significant progress in European and UK markets. The company also advances its psychedelic medicines pipeline, positioning itself for sustained growth.

Bioxyne Limited, through its subsidiary Breathe Life Sciences, has secured a significant supply agreement to enter Germany’s burgeoning medical cannabis market, promising at least A$5.6 million in revenue for FY2026.